Navigation Links
Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
Date:5/18/2012

HACKENSACK, N.J., May 18, 2012 /PRNewswire/ -- Champions Oncology Inc. (OTC: CSBR) announced today that it has received U.S. Clinical Laboratory Improvement Amendment (CLIA) certification from the Maryland Department of Health and Mental Hygiene Office of Health Care Quality required for the company to conduct medical laboratory tests.

The Company's President, Ronnie Morris, MD commented, "Obtaining CLIA approval is a significant milestone for our Company. This approval validates the quality of our laboratory, which operates with a focus on providing high quality services. This certification will reinforce to both our patients and sponsors who utilize our technology that we are achieving the high standards we set as a Company."

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company's Tumorgraft™ Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs.  The Company is building its Tumorgraft™ Technology Platform through the procurement, development and characterization of numerous Tumorgrafts™ within each of several cancer types.  Tumorgrafts™ are procured through agreements with a number of institutions in the U.S. and overseas as well as through its POS business.  The Tumorgrafts™ are developed and tested through agreement with a United States-based preclinical facility.

The Company provides POS to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate.  Additionally, the Company offers Personalized Tumorgraft™ development, drug studies and genome sequencing as part of its POS whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.

CONTACT: Joel Ackerman, +1-201-808-8400


'/>"/>
SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
5. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
6. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
9. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... 2017 , ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, ... by the Parenteral Drug Association (PDA), the New York Interphex Show will open on ... and more than 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... biotech companies, recently announced it will debut a brand new pressure vessel, the ... intelliVessel is controlled by a touch screen panel and features other revolutionary operations ...
(Date:3/20/2017)... Yorba Linda, CA (PRWEB) , ... March 20, ... ... interference and require expensive and laborious sample preparation methods in order to reduce ... is often underappreciated outside of the area of elemental analysis. , This ...
(Date:3/20/2017)... , ... March 20, 2017 , ... The fourth annual ... while innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... challenge every 5 weeks and awards thousands in cash prizes to engineers, inventors and ...
Breaking Biology Technology:
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):